Baxter Wins Some Relief on Nevakar Blood-Pressure Drug Patents

Baxter Healthcare Corp.’s injectable drug for treating severely low blood pressure doesn’t literally infringe five Nevakar Injectables Inc. patents, but may still infringe under a different legal theory, a federal magistrate judge ruled.

Magistrate Judge Christopher J. Burke found no “literal direct infringement” by Baxter’s products of US Patent Nos. 10,420,735, 10,471,026, 10,568,850, 10,646,458, and 11,602,508 because they don’t include a separate ingredient to stabilize the solution, according to an opinion issued March 14 in the US District Court for the District of Delaware. He allowed Nevakar’s claims of infringement under the doctrine of equivalents to ...